The assessment discusses 58 peptides in numerous clinical phases, indicating a sturdy pipeline of peptide therapies targeting PPIs. Clinical trials and preclinical studies are highlighted, exhibiting the efficacy of peptide vaccines in inducing an immune response, with the prospective to boost survival premiums for HCC people. Similarities an